CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its blockbuster Entresto heart failure treatment.
Breakdown
- Novartis raised its operating income outlook after strong second-quarter results.
- Net sales rose 11% and operating income increased by 21%. 10s
- A $10 billion share buyback was announced, reflecting confidence in future growth. 24s
- Novartis is diversifying its portfolio beyond Entresto, highlighting drugs for breast cancer, multiple sclerosis, and cholesterol. 40s
- The company faces challenges from upcoming US patent expiry for Entresto and potential US tariffs, but has not yet commented on the tariffs. 1m 3s